KA-3009

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameKA-3009
Drug Alias NameKA-3009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-CD276Anti-Tumor necrosis factor receptor superfamily member 9
TargetsEpidermal growth factor receptor erbB1CD276 antigenTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKYinno Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKYinno Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A